共 3 条
[1]
Liver insufficiency as a factor modifying the pharmacokinetic characteristic of the preparation nabumetone. Maleev A,Vlahov V,Cruev I,et al. International Journal of Clinical Pharmacology Research . 1986
[2]
Nabumctone pharmacokineties in patients with varying degrees of renal impairment. Boelacrt JR,Jonnaert HA,Schurgers ML,et al. The American Journal of Medicine . 1987
[3]
Nabumetone (Brl 14777, 4-[6-met-hoxy-2-naphyl]-butan-2-one): a new anti-inflammatory agent. Boyle EA,Freeman PC,Mangan FR,et al. Journal of Pharmacokinetics and Pharmacodynamics . 1982